p53 binds and represses the HBV enhancer: An adjacent enhancer element can reverse the transcription effect of p53

EMBO Journal

Volumn 17, Issue 2, 1998, Pages 544-553

  Ori, Assaf ^a   Zauberman, Arie ^a   Doitsh, Gilad ^a   Paran, Nir ^a   Oren, Moshe ^a   Shaul, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

DNA damage; Enhancer; HBV; mdm2 promoter; p53 repression; Transcription regulation

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR;

ARTICLE; ENHANCER REGION; GENE MUTATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CELL LINE; CISPLATIN; DNA DAMAGE; DNA, VIRAL; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENES; REGULATORY SEQUENCES, NUCLEIC ACID; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0032518913     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/17.2.544     Document Type: Article

References (69)

1. Agami, R. and Shaul, Y. (1998) The kinase activity of C-Abl but not V-Abl is potentiated by direct interaction with RFX1, a protein that binds the enhancers of several viruses and cell-cycle regulated genes. Oncogene, in press.
2. Agoff, S.N., Hou, J., Linzer, D.I. and Wu, B. (1993) Regulation of the human hsp70 promoter by p53. Science, 259, 84-87.
3. Aoyama, N., Nagase, T., Sawazaki, T., Mizuguchi, G., Nakagoshi, H., Fujisawa, J.I., Yoshida, M. and Ishii, S. (1992) Overlap of the p53-responsive element and cAMP-responsive element in the enhancer of human T-cell leukemia virus type I. Proc. Natl Acad. Sci. USA, 89, 5403-5407.
4. Barak, Y., Gottlieb, E., Juven, G.T. and Oren, M. (1994) Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev., 8, 1739-1749.
5. Bargonetti, J., Friedman, P.N., Kern, S.E., Vogelstein, B. and Prives, C. (1991) Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell, 65, 1083-1091.
6. Beasley, R.P., Lin, C.C., Hwang, L.Y. and Chien, C.S. (1981) Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet, ii, 1129-1133.
7. Ben-Levy, R., Faktor, O., Berger, I. and Shaul, Y. (1989) Cellular factors that interact with the hepatitis B virus enhancer. Mol. Cell. Biol., 9, 1804-1809.
8. Chen, P.L., Chen, Y.M., Bookstein, R. and Lee, W.H. (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-1580.
9. Dikstein, R., Faktor, O., Ben-Levy, R. and Shaul, Y. (1990a) Functional organization of the hepatitis B virus enhancer. Mol. Cell. Biol., 10, 3682-3689.
10. Dikstein, R., Faktor, O. and Shaul, Y. (1990b) Hierarchic and cooperative binding of the rat liver nuclear protein C/EBP at the hepatitis B virus enhancer. Mol. Cell. Biol., 10, 4427-4430.
11. Dikstein, R., Heffetz, D., Ben-Neriah, Y. and Shaul, Y. (1992) c-Abl has a sequence-specific enhancer binding activity. Cell, 69, 751-757.
12. Dikstein, R., Agami, R., Heffetz, D. and Shaul, Y. (1996) p140/c-Abl that binds DNA is preferentially phosphorylated at tyrosine residues. Proc. Natl Acad. Sci. USA, 93, 2387-2391.
13. Duyster, J., Baskaran, R. and Wang, J. Y. (1995) Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc. Natl Acad. Sci. USA, 92, 1555-1559.
14. El-Deiry, W., Kern, S.E., Pietenpol, J.A., Kinzler, K.W. and Vogelstein, B. (1992) Definition of a consensus binding site for p53. Nature Genet., 1, 45-49.
15. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi, K.O. and Oren, M. (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl Acad. Sci. USA, 86, 8763-8767.
16. Etiemble, J., Degott, C., Renard, C.A., Fourel, G., Shamoon, B., Vitvitski, T.L., Hsu, T. Y., Tiollias, P., Babinet, C. and Buendia, M.A. (1994) Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion. Oncogene, 9, 727-737.
17. Faktor, O. and Shaul, Y. (1990) The identification of hepatitis B virus X gene responsive elements reveals functional similarity of X and HTLVI tax. Oncoeene, 5, 867-872.
18. Faktor, O., Budlovsky, S., Ben-Levy, R. and Shaul, Y. (1990) A single element within the hepatitis B virus enhancer binds multiple proteins and responds to multiple stimuli. J. Virol., 64, 1861-1863.
19. Friedlander, P. Haupt, Y., Prives, C. and Oren, M. (1996) A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol., 16, 4961-4971.
20. Fritsche, M., Haessler, C. and Brandner, G. (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8, 307-318.
21. Garcia, A.D., Ostapchuk, P. and Hearing, P. (1993) Functional interaction of nuclear factors EF-C, HNF-4, and RXRa with hepatitis B virus enhancer I. J. Virol., 67, 3940-3950.
22. Ginsberg, D., Mechta, F., Yaniv, M. and Oren, M. (1991) Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl Acad. Sci. USA, 88, 9979-9983.
23. Gottlieb, T.M. and Oren, M. (1996) p53 in growth control and neoplasia. Biochim. Biophys. Acta. 1287, 77-102.
24. Haffner, R. and Oren, M. (1995) Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev., 5, 84-90.
25. Haviv, I., Vaizel, D. and Shaul, Y. (1995) The X protein of the hepatitis B virus coactivates acidic activation domains. Mol. Cell. Biol., 15, 1079-1085.
26. Honigwachs, J., Faktor, O., Dikstein, R., Shaul, Y. and Laub, O. (1989) Liver-specific expression of hepatitis B virus is determined by the combined action of the core gene promoter and the enhancer. J. Virol., 63, 919-924.
27. Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1993) Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res., 21, 3167-3174.
28. Jameel, S. and Siddiqui, A. (1986) The human hepatitis B virus enhancer requires trans-acting cellular factor(s) for activity. Mol. Cell. Biol., 6, 710-715.
29. Juven, T., Barak, Y. Zauberman, A., George, D.L. and Oren, M. (1993) Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene, 8, 3411-3416.
30. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R.W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
31. Katan, Y., Agami, R. and Shaul, Y. (1997) The transcriptional activation and repression domains of RFX1, a context-dependent regulator, can mutually neutralize their activities. Nucleic Acids Res., 28, 3621-3628.
32. Kern, S.E., Kinzler, K.W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C. and Vogelstein, B. (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science, 252, 1708-1711.
33. Kley, N., Chung, R.Y., Fay, S., Loeffler, J.P. and Seizinger, B.R. (1992) Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res., 20, 4083-4087.
34. Ko, L.J. and Prives, C. (1996) p53: puzzle and paradigm. Genes Dev., 10, 1054-1072.
35. Lee, H., Lee, Y.H., Huh, Y.S., Moon, H. and Yun, Y. (1995) X-gene product antagonizes the p53-mediated inhibition of hepatitis B virus replication through regulation of the pregenomic/core promoter. J. Biol. Chem., 270, 31405-31412.
36. Liu, X., Miller, C.W., Koeffler, P.H. and Berk, A.J. (1993) The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol., 13, 3291-3300.
37. Lu, H. and Levine, A.J. (1995) Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl Acad. Sci. USA, 92, 5154-5158.
38. Maguire, H.F., Hoeffler, J.P. and Siddiqui, A. (1991) HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science, 252, 842-844.
39. Martin, D.W., Munoz, R.M., Subler, M.A. and Deb, S. (1993) p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem., 268, 13062-13067.
40. Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. and Cline, M.J. (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl Acad. Sci. USA, 84, 7716-7719.
41. Michalovitz, D., Halevi, O. and Oren, M. (1990) Conditional inhibition of transformation and of cell proliferation by temperature-sensitive mutant of p53. Cell, 62, 671-680.
42. Miyashita, T. and Reed, J.C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell, 80, 293-299.
43. Moberg, K.H., Tyndall, W.A. and Hall, D.J. (1992) Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line. J. Cell. Biochem., 49, 208-215.
44. Murphy, M., Hinman, A. and Levine, A.J. (1996) Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev., 10, 2971-2980.
45. Okamoto, K. and Beach, D. (1994) Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J., 13, 4816-4822.
46. Ori, A. and Shaul, Y. (1995) Hepatitis B virus enhancer binds and is activated by hepatocyte nuclear factor 3. Virology, 207, 98-106.
47. Ostapchuk, P., Scheirle, G. and Hearing, P. (1989) Binding of nuclear factor EF-C to a functional domain of the hepatitis B virus enhancer region. Mol. Cell. Biol., 9, 2787-2797.
48. Patel, N.U., Jameel, S., Isom, H. and Siddiqui, A. (1989) Interactions between nuclear factors and the hepatitis B virus enhancer. J. Virol., 63, 5293-5301.
49. Ponchel, F., Puisieux, A., Tabone, E., Michot, J.P., Froschl, G., Morel, A.P., Frebourg, T., Fontaniere, B., Oberhammer, F. and Ozturk, M. (1994) Hepatocarcinoma-specific mutant p53-249Ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res., 54, 2064-2068.
50. Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M. and Aloni, Y. (1993) Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene, 8, 1183-1193.
51. Reith, W., Ucla, C., Barras, E., Gaud, A., Durand, B., Herrero, S.C., Kobr, M. and Mach, B. (1994) RFX1, a transactivator of hepatitis B virus enhancer I, belongs to a novel family of homodimeric and heterodimeric DNA-binding proteins. Mol. Cell. Biol., 14, 1230-1244.
52. Santhanam, U., Ray, A. and Sehgal, P.B. (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl Acad. Sci. USA, 88, 7605-7609.
53. Seto, E., Usheva, A., Zambetti, G.P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A.J. and Shenk, T. (1992) Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 89, 12028-12032.
54. Shaul, Y. and Ben-Levy, R. (1987) Multiple nuclear proteins in liver cells are bound to hepatitis B virus enhancer element and its upstream sequences. EMBO J., 6, 1913-1920.
55. Shaul, Y., Rutter, W.J. and Laub, O. (1985) A human hepatitis B viral enhancer element. EMBO J., 4, 427-430.
56. Shaul, Y., Ben-Levy, R. and De-Medina, T. (1986) High affinity binding site for nuclear factor I next to the hepatitis B virus S gene promoter. EMBO J., 5, 1967-1971.
57. Shaulian, E., Zauberman, A., Ginsberg, D. and Oren, M. (1992) Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol., 12, 5581-5592.
58. Shiio, Y., Yamamoto, T. and Yamaguchi, N. (1992) Negative regulation of Rb expression by the p53 gene product. Proc. Natl Acad. Sci. USA, 89, 5206-5210.
59. Siegrist, C.A., Durand, B., Emery, P., David, E., Hearing, P., Mach, B. and Reith, W. (1993) RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer. Mol. Cell. Biol., 13, 6375-6384.
60. Subler, M.A., Martin, D.W. and Deb, S. (1992) Inhibition of viral and cellular promoters by human wild-type p53. J. Virol., 66, 4757-4762.
61. Thut, C.J., Chen, J.L., Klemm, R. and Tjian, R. (1995) p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science, 267, 100-104.
62. Trujillo, M.A., Letovsky, J., Maguire, H.F., Lopez, C.M. and Siddiqui, A. (1991) Functional analysis of a liver-specific enhancer of the hepatitis B virus. Proc. Natl Acad. Sci. USA, 88, 3797-3801.
63. Wei, Y., Fourel, G., Ponzetto, A., Silvestro, M., Tiollais, P. and Buendia, M.A. (1992) Hepadnavirus integration: mechanisms of activation of the N-myc2 retrotransposon in woodchuck liver tumors. J. Virol., 66, 5265-5276.
64. Weintraub, H., Hauschka, S. and Tapscott, S.J. (1991) The MCK enhancer contains a p53 responsive element. Proc. Natl Acad. Sci. USA, 88, 4570-4571.
65. Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. (1993) The p53-mdm2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132.
66. Yuan, Z.-M., Huang, Y., Whang, Y., Sawyers, C., Weichselbaum, R., Kharbanda, S. and Kufe, D. (1996) Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature, 382, 272-274.
67. Zambetti, G.P., Bargonetti, J., Walker, K., Prives, C. and Levine, A.J. (1992) Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 6, 1143-1152.
68. Zauberman, A., Barak, Y., Ragimov, N., Levy, N. and Oren, M. (1993) Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J., 12, 2799-2808.
69. Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y. and Oren, M. (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res, 23, 2584-2592.